Long Term Clinical Investigation to Evaluate Clinical Performance, Safety and Patient Reported Outcomes of an Active Osseointegrated Steady-State Implant System

Sponsor
Cochlear (Industry)
Overall Status
Completed
CT.gov ID
NCT04754477
Collaborator
Statistiska Konsultgruppen (Other)
20
3
1
10.5
6.7
0.6

Study Details

Study Description

Brief Summary

The aim of this clinical investigation is to collect long-term safety and performance data with the Active Osseointegrated Steady-State Implant System by following subjects from the previous Osia clinical investigation CBAS5751. In addition, questions regarding device satisfaction, sound satisfaction, usability and health care utilisation will be asked.

Condition or Disease Intervention/Treatment Phase
  • Device: Active Osseointegrated Steady-State Implant System (OSI)
N/A

Study Design

Study Type:
Interventional
Actual Enrollment :
20 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Multicentre, Open, Long-term Clinical Investigation Evaluating Safety, Performance and Patient Reported Outcomes With an Active Osseointegrated Steady-State Implant System in Adult Subjects With Conductive Hearing Loss, Mixed Hearing Loss or Single-sided Sensorineural Deafness.
Actual Study Start Date :
May 6, 2021
Actual Primary Completion Date :
Mar 21, 2022
Actual Study Completion Date :
Mar 21, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Active Osseointegrated Steady-State Implant System (OSI)

Device: Active Osseointegrated Steady-State Implant System (OSI)
System includes the OSI200 implant surgically placed under the skin behind the ear, the BI300 implant osseointegrated in the bone and the external Osia 2 sound process

Outcome Measures

Primary Outcome Measures

  1. Number and type of reported Adverse events [6 months post-surgery to 24 months post-surgery]

    The adverse events are collected from the participant's last visit in study CBAS5751 (6 months post-surgery) and categorized by system organ class system

  2. Number and type of reported Device deficiencies [6 months post-surgery to 24 months post-surgery]

    The device deficiencies are collected from the participant's last visit in study CBAS5751 (6 months post-surgery) and categorized by relationship

  3. Concomitant medication used [6 months post-surgery to 24 months post-surgery]

    Concomitant medication are collected from the participant's last visit in study CBAS5751 (6 months post-surgery)

  4. Socio-economic health care data via the Client Service Receipt Inventory (CSRI) survey [12 months post-surgery]

    Demographic data (marital status, cohabitation, usual place of residence, education level), employment status, Healthcare utilization and Hearing rehabilitation data are collected

  5. Socio-economic health care data via the Client Service Receipt Inventory (CSRI) survey [24 months post-surgery]

    Demographic data (marital status, cohabitation, usual place of residence, education level), employment status, Healthcare utilization and Hearing rehabilitation data are collected

  6. Change in audiometric thresholds with the Active Osseointegrated Steady-State Implant System at 12 months post-surgery and 24 months post-surgery compared to preoperative thresholds via an audiogram [Baseline before surgery, 12 months and 24 months post-surgery]

    Bone- and air conduction thresholds, masked and unmasked

Secondary Outcome Measures

  1. Change in hearing performance with the Active Osseointegrated Steady-State Implant System at 12 months and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study assessed via audiometric thresholds [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Sound-field (Pure Tone Average 4, mean of 0.5, 1, 2 and 4 kHz)

  2. Change in hearing performance with the Active Osseointegrated Steady-State Implant System at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study assessed via audiometric thresholds [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Sound-field [0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0 and 8.0 kHz]

  3. Change in hearing performance with the Active Osseointegrated Steady-State Implant System at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study assessed via adaptive speech recognition in noise [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Speech-to-noise ratio, 50% speech understanding

  4. Change in hearing performance with the Active Osseointegrated Steady-State Implant System at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study assessed via Bone Conduction (BC) direct [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    BC direct (0.25, 0.5, 0.75, 1.0, 1.5, 2.0, 3.0, 4.0 and 6.0 kHz)

  5. Difference in self-reported hearing outcome with the Active Osseointegrated Steady-State Implant System at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Assessed via Abbreviated Profile of Hearing Aid Benefit (APHAB) questionnaire. APHAB produces a global score and scores for four subscales: Ease of Communication, Reverberation, Background Noise, and Aversiveness. Global score is the average of all subscales. All scales range from 0-100%, where 0% indicates no problem and 100% indicates always problem. A decrease in the APHAB values indicates an improvement. The difference in scores will be presented. A positive value indicates an improvement, a negative value an impairment.

  6. Change in self-reported hearing outcome with the Active Osseointegrated Steady-State Implant System at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Assessed via the Speech, Spatial and Qualities of Hearing Scale (SSQ) questionnaire. Measuring change of speech, spatial and hearing experiences with the Active Osseointegrated Steady-State Implant System. The Total score summarizes the parameters speech, spatial and hearing. A scale from 0 to 10 is used, where 0 represents "can not hear at all", and 10 "hear perfectly". An increase of an SSQ value reflects an improvement. The change in scores will be presented. A positive value indicates improved hearing, a negative value indicates impaired hearing.

  7. Change in health-related quality of life with the Active Osseointegrated Steady-State Implant System at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Assessed via the Health Utilities Index (HUI) questionnaire. Change of health status and health related quality of life using the generic quality of life scale Health Utilities Index when wearing the Active Osseointegrated Steady-State Implant System. A health utility value of 1.00 indicates perfect health while a score of 0.00 indicates death. The change in scores will be presented. A positive value indicates an improved quality of life, a negative value indicates impaired quality of life.

  8. Participant satisfaction with the investigational device (every-day situation and self-esteem) assessed on a Likert Scale [12 months post-surgery]

    To express how much they agree or disagree with a particular statement. The scale goes from 1 to 7, where 1 represent Much worse and 7 represent Much better.

  9. Participant satisfaction with the investigational device (easiness to use) assessed on a Likert Scale [12 months post-surgery]

    To express how much they agree or disagree with a particular statement. The scale goes from 1 to 5 where 1 represent Very difficult and 5 represent Very easy.

  10. Participant satisfaction with the investigational device (durability of the device and sound quality) assessed on a Likert Scale [12 months post-surgery]

    To express how much they agree or disagree with a particular statement. The scale goes from 1 to 5, where 1 represent Very dissatisfied and 5 represent Very satisfied.

  11. Participant satisfaction with the investigational device (overall satisfaction) with question Yes/No. [12 months post-surgery]

  12. Participant satisfaction with the investigational device (every-day situation and self-esteem) assessed on a Likert Scale [24 months post-surgery]

    To express how much they agree or disagree with a particular statement. The scale goes from 1 to 7, where 1 represent Much worse and 7 represent Much better.

  13. Participant satisfaction with the investigational device (easiness to use) assessed on a Likert Scale [24 months post-surgery]

    To express how much they agree or disagree with a particular statement. The scale goes from 1 to 5 where 1 represent Very difficult and 5 represent Very easy.

  14. Participant satisfaction with the investigational device (durability of the device and sound quality) assessed on a Likert Scale [24 months post-surgery]

    To express how much they agree or disagree with a particular statement. The scale goes from 1 to 5, where 1 represent Very dissatisfied and 5 represent Very satisfied.

  15. Participant satisfaction with the investigational device (overall satisfaction) with question Yes/No. [24 months post-surgery]

  16. Change in daily use of the Osia 2 sound processor at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Average hours of daily use during the last week before each follow up visit

  17. Change in daily streaming time of the Osia 2 sound processor at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Average hours of daily streaming during the last week before each follow up visit

  18. Change in battery lifetime of the Osia 2 sound processor at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Average hours of battery lifetime for a single battery during the last week before each follow up visit

  19. Change in magnet choice of the Osia 2 sound processor at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Magnet strength ranging from 1 to 4, strength 1 being the weakest and 4 the strongest. If the magnet strength has been changed the reason for change is captured in free text

  20. Change in use of SoftWear pad for the Osia 2 sound processor at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    SoftWear pad usage: Yes or No

  21. Change in retention of the Osia 2 sound processor at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Assessed via a Visual Analog Scale (VAS) 100 mm where 0 mm represents insufficient retention and 100 mm excellent retention.

  22. Change in wearing comfort of the Osia 2 sound processor at 12 and 24 months post-surgery compared to last performed measurement (3 or 6 months) in the CBAS5751 study [3 or 6 months post-surgery, 12 and 24 months post-surgery]

    Assessed via a Visual Analog Scale (VAS) 100 mm where 0 mm represents no comfort at all and 100 mm excellent comfort.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Subject has performed Hearing assessment at 3 and/or 6 months in the clinical investigation CBAS5751

  • Willing and able to provide written informed consent

Exclusion Criteria:
  • Unable to follow investigational procedures, e.g. to complete quality of life scales, or unwilling to comply with the requirements of the clinical investigation as determined by the investigator

  • Use of ototoxic drugs that could be harmful to the hearing, as judged by the investigator

Contacts and Locations

Locations

Site City State Country Postal Code
1 SCIC / NextSense Gladesville New South Wales Australia 2111
2 HEARnet Clinical studies Carlton Victoria Australia 3053
3 Department of Otorhinolaryngology, Head and Neck Surgery Faculty of Medicine. The Chinese University of Hong Kong Hong Kong Hong Kong

Sponsors and Collaborators

  • Cochlear
  • Statistiska Konsultgruppen

Investigators

  • Study Director: Karin Ganlöv, MD, Cochlear

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cochlear
ClinicalTrials.gov Identifier:
NCT04754477
Other Study ID Numbers:
  • CBAS5793
First Posted:
Feb 15, 2021
Last Update Posted:
Mar 25, 2022
Last Verified:
Mar 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Cochlear
Additional relevant MeSH terms:

Study Results

No Results Posted as of Mar 25, 2022